Axcelis Technologies, Inc. has announced an updated timeline for its merger with Veeco Instruments Inc., now expected to close by the end of the first quarter of 2027. This update comes as both companies navigate the regulatory landscape to finalize the all-stock transaction.

The merger, originally announced on September 30, 2025, will see Veeco become a wholly owned subsidiary of Axcelis. The completion of the merger is contingent upon satisfying various customary closing conditions, including regulatory approvals from the State Administration for Market Regulation of China and compliance with the Hart-Scott-Rodino Antitrust Improvements Act.

Axcelis Technologies, headquartered in Beverly, Massachusetts, specializes in providing innovative solutions for the semiconductor industry. The company is recognized for its high-productivity ion implantation systems, which are essential in the manufacturing process of integrated circuits. The merger with Veeco, a manufacturer of semiconductor process equipment, aims to enhance Axcelis's market position and expand its offerings in the semiconductor equipment sector.

In the latest filing, Axcelis indicated that they are actively working with regulatory bodies to secure the necessary approvals. The companies are also preparing to submit a new filing under the HSR Act due to the impending expiration of their current clearance.

The merger is set to convert each share of Veeco common stock into 0.3575 shares of Axcelis at closing. This strategic move is expected to position the combined entity as a leader in the semiconductor equipment market, serving a diverse range of end markets.

As the merger progresses, stakeholders will be keenly watching for updates regarding regulatory approvals and any potential impacts on the industry landscape. The anticipated closing timeline reflects the companies' commitment to completing the merger while navigating the complexities of regulatory compliance.

For now, both Axcelis and Veeco continue to prepare for the merger, with the next steps likely involving further regulatory discussions and compliance measures.